Evidence map›Paper›PMID 27083182›Full record

ArticleBreast cancer research and treatment2016

Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes.

Kristen S Purrington, Daniel W Visscher, Chen Wang, Drakoulis Yannoukakos, Ute Hamann, Heli Nevanlinna, Angela Cox, Graham G Giles, Jeanette E Eckel-Passow, Sotiris Lakis and 21 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Rare Breast Cancer Subtypes.Current oncology reports · 2021
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 11 institutions in 6 countries.

Kristen S PurringtonDepartment of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, USA.
Daniel W VisscherDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA.
Chen WangDepartment of Health Sciences Research, Mayo Clinic, Stabile 2-42, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Drakoulis YannoukakosMolecular Diagnostics Laboratory INRASTES, National Centre for Scientific Research "Demokritos", Athens, Greece.
Ute HamannMolecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heli NevanlinnaDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
Angela CoxDepartment of Oncology, University of Sheffield, Sheffield, UK.
Graham G GilesCancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia.
Jeanette E Eckel-PassowDepartment of Health Sciences Research, Mayo Clinic, Stabile 2-42, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Sotiris LakisLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.
Vassiliki KotoulaLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.
George FountzilasLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.
Maria KabischMolecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Thomas RüdigerInstitute of Pathology, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.
Päivi HeikkiläDepartment of Pathology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
Carl BlomqvistDepartment of Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
Simon S CrossDepartment of Neuroscience, University of Sheffield, Sheffield, UK.
Melissa C SoutheyGenetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Melbourne, Australia.
Janet E OlsonDepartment of Health Sciences Research, Mayo Clinic, Stabile 2-42, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Judy GilbertDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA.
Sandra Deming-HalversonDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, USA.
Veli-Matti KosmaImaging Center, Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland.
Christine ClarkeCentre for Cancer Research, University of Sydney at the Westmead Millennium Institute, Westmead, Australia.
Rodney ScottDivision of Genetics, Hunter Area Pathology Service and University of Newcastle, Newcastle, Australia.
J Louise JonesBarts Cancer Research Institute, Queen Mary University of London, London, UK.
Wei ZhengDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, USA.
Arto MannermaaImaging Center, Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland.
Jane Carpenter for ABCTC Investigators
Diana M EcclesFaculty of Medicine and NIHR/CRUK Clinical Trials Unit, University of Southampton, Southampton, UK.
Celine M VachonDepartment of Health Sciences Research, Mayo Clinic, Stabile 2-42, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Fergus J CouchDepartment of Health Sciences Research, Mayo Clinic, Stabile 2-42, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. couch.fergus@mayo.edu.
Mayo Clinic · USUniversity of Helsinki · FIGerman Cancer Research Center · DEAristotle University of Thessaloniki · GRQueen Mary University of London · GBThe University of Sydney · AUVanderbilt University · USCancer Council Victoria · AUThe University of Melbourne · AUUniversity of Eastern Finland · FIWayne State University · US

Funding

The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
Risk and penetrance of mutations from breast cancer testing panels.R01CA192393 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH, NATHANSON, KATHERINE L. · 2014 to 2018
$6.3M
Mayo Cancer Genetic Epidemiology Training ProgramR25CA092049 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M., VACHON, CELINE M · 2001 to 2018
$5.3M
The Nashville Breast Health StudyR01CA100374 · NCI · VANDERBILT UNIVERSITY · PI ZHENG, WEI · 2004 to 2009
$4.2M
BRCA2 missense mutations and breast cancerR01CA116167 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH · 2007 to 2011
$3.0M
BRCA1 and BRCA2 missense mutations and breast cancer riskU01CA116167 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH · 2013 to 2017
$2.7M
NCI NIH HHS P50 CA116201NCI NIH HHS R01 CA100374NCI NIH HHS R01 CA116167NCI NIH HHS R01 CA192393NCI NIH HHS R25 CA092049NCI NIH HHS U01 CA116167
6 · The paper itself

Abstract

Distinct subtypes of triple negative (TN) breast cancer have been identified by tumor expression profiling. However, little is known about the relationship between histopathologic features of TN tumors, which reflect aspects of both tumor behavior and tumor microenvironment, and molecular TN subtypes. The histopathologic features of TN tumors were assessed by central review and 593 TN tumors were subjected to whole genome expression profiling using the Illumina Whole Genome DASL array. TN molecular subtypes were defined based on gene expression data associated with histopathologic features of TN tumors. Gene expression analysis yielded signatures for four TN subtypes (basal-like, androgen receptor positive, immune, and stromal) consistent with previous studies. Expression analysis also identified genes significantly associated with the 12 histological features of TN tumors. Development of signatures using these markers of histopathological features resulted in six distinct TN subtype signatures, including an additional basal-like and stromal signature. The additional basal-like subtype was distinguished by elevated expression of cell motility and glucose metabolism genes and reduced expression of immune signaling genes, whereas the additional stromal subtype was distinguished by elevated expression of immunomodulatory pathway genes. Histopathologic features that reflect heterogeneity in tumor architecture, cell structure, and tumor microenvironment are related to TN subtype. Accounting for histopathologic features in the development of gene expression signatures, six major subtypes of TN breast cancer were identified.

Indexed as

Gene Regulatory NetworksAdultAgedFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGerm-Line MutationHumansMiddle AgedSequence Analysis, RNATriple Negative Breast NeoplasmsBreast cancerGene expressionGermline mutationPathologyTumor biology

Identifiers

PMID27083182
PMCPMC5400013
OpenAlexW2341263524

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.